Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Catalent Stock Jumps on $16.5 Billion Sale to Controlling Shareholder of Ozempic Maker Novo Nordisk
06:38am, Monday, 05'th Feb 2024
Novo Holdings will acquire Catalent for $63.50 a share in cash.
Novo Nordisk's controlling shareholder to buy Catalent for $16.5 billion
06:15am, Monday, 05'th Feb 2024
Novo Holdings, the controlling shareholder of Novo Nordisk NVO, -1.80%, said it's buying Catalent CTLT, +2.67% for $16.5 billion in cash, or $63.50 per Catalent share, a 16.5% premium to Friday's clos
It's shaping up to be a great quarter for Europe's biggest companies — no thanks to Europe.
03:59am, Monday, 05'th Feb 2024
Fourth-quarter earnings season in Europe is still in its early days, but the largest companies on the Continent are mostly hitting their stride.
Is Novo Nordisk a Hot Stock to Buy Now After its Spectacular Q4?
02:59am, Monday, 05'th Feb 2024
Novo Nordisk is one of the pharmaceutical stocks of the moment. And it just delivered an estimate-busting earnings report.
3 Reasons Growth Investors Will Love Novo Nordisk (NVO)
01:46pm, Friday, 02'nd Feb 2024
Novo Nordisk (NVO) could produce exceptional returns because of its solid growth attributes.
4 Large Drug Stocks Trying to Survive the Industry Challenges
09:51am, Friday, 02'nd Feb 2024
Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), AbbVie (ABBV) and Novartis (NVS) are worth retainin
The Road to a Trillion: 3 Stocks Next in Line for the Mega Milestone
11:28am, Thursday, 01'st Feb 2024
“A billion here, a billion there, and pretty soon you're talking real money.” While a trillion-dollar price tag is likely more common in today's inflationary times, only a handful of companies hav
Novo Nordisk still a buy for Citi as return on capital hits 88%
08:47am, Thursday, 01'st Feb 2024
Novo Nordisk (NYSE:NVO) remains a buy for US bank Citigroup even though it is only the second European company in history to pass the half-a-trillion mark after LVMH temporarily hit the landmark last
Obesity product competition benefits companies and society: Novo Nordisk
06:30am, Thursday, 01'st Feb 2024
Novo Nordisk CEO Lars Fruergaard Jørgensen speaks to CNBC following blockbuster earnings from Europe's largest company, driven by soaring demand for its obesity and diabetes drugs Wegovy and Ozempic.
Obesity drug supply-demand imbalance is working in Novo Nordisk's favor: Mizuho's Jared Holz
06:23pm, Wednesday, 31'st Jan 2024
Jared Holz, Mizuho Securities, joins 'Fast Money' to talk demand in the obesity drug space and who is benefiting from the supply-demand imbalance.
Novo Nordisk CFO discusses 36% surge in sales driven by Wegovy and Ozempic
04:10pm, Wednesday, 31'st Jan 2024
Pharmaceutical giant Novo Nordisk (NVO) reported a 36% surge in sales thanks to high demand for weight loss drugs Wegovy and Ozempic. Novo Nordisk CFO Karsten Munk Knudsen joins Yahoo Finance Senior H
Novo Nordisk increasing supply of Wegovy as demand continues to grow
03:55pm, Wednesday, 31'st Jan 2024
Novo Nordisk says it Is gradually ramping up supply of its sought-after drug Wegovy. However, the company is still warning patients demand will still outpace supply overall.
Private-Sector Payrolls Declined More Than Expected
11:56am, Wednesday, 31'st Jan 2024
January Jobs Week continues this morning, even as we're only just closing out the month today. Private-sector payrolls reported by Automatic Data Processing ( ADP ) came in below estimates: 107K versu
Ozempic and Wegovy maker Novo Nordisk now worth $500B amid soaring popularity
11:39am, Wednesday, 31'st Jan 2024
The drug maker vaulted ahead of luxury goods maker LVMH to claim the title of Europe's most valuable company.
ADP Cools to 107K Private-Sector Jobs; BA, NVO Beat in Q4
11:26am, Wednesday, 31'st Jan 2024
We've now spent a full six months sub-200K private-sector job gains per month.
